Clinical Trials Directory

Trials / Unknown

UnknownNCT02610712

Clinical Trial of the Use of Ketamine in Treatment Resistant Depression

Status
Unknown
Phase
Phase 4
Study type
Interventional
Enrollment
20 (estimated)
Sponsor
National Institute of Neurology and Neurosurgery, Mexico · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine the efficacy of the use of intravenous low-dose ketamine in the treatment of treatment-resistant depression (TRD), as well as the changes in Glutamate neurotransmission and inflammatory serum markers.

Detailed description

The purpose of this study is to determine the efficacy of the use of intravenous low-dose ketamine (0.5 mg/kg) in the treatment of treatment-resistant depression (TRD), as well as the changes in Glutamate neurotransmission measured by Magnetic Resonance Imaging Spectroscopy and inflammatory serum markers (IL-6, TNF-alpha).

Conditions

Interventions

TypeNameDescription
DRUGKetamine

Timeline

Start date
2014-05-01
Primary completion
2017-12-01
First posted
2015-11-20
Last updated
2016-09-21

Locations

1 site across 1 country: Mexico

Source: ClinicalTrials.gov record NCT02610712. Inclusion in this directory is not an endorsement.

Clinical Trial of the Use of Ketamine in Treatment Resistant Depression (NCT02610712) · Clinical Trials Directory